Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...

Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as ...

A new pill designed to help with weight loss and blood sugar control is showing promise in early studies. Eli Lilly said its ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

Eli Lilly (NYSE: LLY) stock jumped over 14% on Thursday, powered by highly promising Phase 3 results for orforglipron, an ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on ...